VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Hamlin on Brentuximab Vedotin Pharmacology

Paul A. Hamlin, MD
Published: Thursday, Jan 26, 2012

Paul A. Hamlin, MD, Clinical Director, Lymphoma Outpatient Unit, Memorial Sloan-Kettering Cancer Center, discusses the drug brentuximab vedotin (Adcetris), which was approved in August 2011 for refractory anaplastic large cell lymphoma and Hodgkin lymphoma.

Hamlin explains that brentuximab vedotin is part of a new branch of drugs known as antibody-drug conjugates. These agents combine the specificity of an antibody, which can target antigens directly on the surface of the cancer cell, with the ability to directly deliver a targeted cytotoxic payload.

The payload agent in brentuximab vedotin is monomethyl auristatin E, which is a microtubulin inhibitor that prevents neoplastic cells from replicating.

View more videos of Paul A. Hamlin, MD.
Paul A. Hamlin, MD, Clinical Director, Lymphoma Outpatient Unit, Memorial Sloan-Kettering Cancer Center, discusses the drug brentuximab vedotin (Adcetris), which was approved in August 2011 for refractory anaplastic large cell lymphoma and Hodgkin lymphoma.

Hamlin explains that brentuximab vedotin is part of a new branch of drugs known as antibody-drug conjugates. These agents combine the specificity of an antibody, which can target antigens directly on the surface of the cancer cell, with the ability to directly deliver a targeted cytotoxic payload.

The payload agent in brentuximab vedotin is monomethyl auristatin E, which is a microtubulin inhibitor that prevents neoplastic cells from replicating.

View more videos of Paul A. Hamlin, MD.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AMLMay 31, 20181.0
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Publication Bottom Border
Border Publication
x